| scholarly article | Q13442814 |
| P50 | author | Carl H. June | Q19277113 |
| Stephan A Grupp | Q104495066 | ||
| David L. Porter | Q110797660 | ||
| Saad S. Kenderian | Q45896559 | ||
| Marco Ruella | Q56947896 | ||
| Simon F Lacey | Q56978267 | ||
| P2093 | author name string | John Scholler | |
| Christopher A Hunter | |||
| Michael Klichinsky | |||
| Olga Shestova | |||
| David M Barrett | |||
| Farzana Nazimuddin | |||
| Saar Gill | |||
| Ted J Hofmann | |||
| Jan J Melenhorst | |||
| Miroslaw Kozlowski | |||
| David A Christian | |||
| Michael Kalos | |||
| Jennifer J D Morrissette | |||
| Vania Aikawa | |||
| Jessica Perazzelli | |||
| P2860 | cites work | T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 |
| The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells | Q28140494 | ||
| Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors | Q28201493 | ||
| CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis | Q28265732 | ||
| Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 | ||
| Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia | Q29617590 | ||
| Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 | ||
| PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses | Q30600094 | ||
| AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells | Q30637447 | ||
| A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates | Q33423181 | ||
| Loss of mismatched HLA in leukemia after stem-cell transplantation. | Q34018719 | ||
| Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells | Q34283399 | ||
| Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. | Q35483880 | ||
| CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia | Q36279306 | ||
| Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy | Q36349583 | ||
| In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. | Q36715919 | ||
| CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients | Q36951727 | ||
| T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells | Q37066770 | ||
| T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. | Q37272020 | ||
| Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. | Q37351577 | ||
| Leukemia stem cells and human acute lymphoblastic leukemia. | Q37355972 | ||
| Mechanisms of resistance to FLT3 inhibitors. | Q37375423 | ||
| A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting | Q84574160 | ||
| Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma | Q84972455 | ||
| Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo | Q37436837 | ||
| Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells | Q37697847 | ||
| Modern therapy of acute lymphoblastic leukemia | Q37827276 | ||
| BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet | Q37874391 | ||
| Relapsed childhood acute lymphoblastic leukaemia | Q38103645 | ||
| Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors | Q38146323 | ||
| Adoptive immunotherapy for cancer. | Q38170496 | ||
| CD123 and its potential clinical application in leukemias. | Q38274851 | ||
| A case of CD45-, CD19- precursor B cell acute lymphoblastic leukemia with an atypical morphology | Q38502987 | ||
| The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates. | Q39014655 | ||
| Kinetics of tumor destruction by chimeric antigen receptor-modified T cells | Q39064900 | ||
| Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. | Q39111239 | ||
| Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells | Q39323781 | ||
| Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. | Q39360350 | ||
| The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. | Q40050634 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. | Q40590332 | ||
| Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells | Q40981186 | ||
| Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. | Q42143237 | ||
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 | ||
| Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia | Q43457128 | ||
| Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study | Q43889424 | ||
| CD19 negative precursor B acute lymphoblastic leukemia presenting with hypercalcemia | Q44916282 | ||
| Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain. | Q45061050 | ||
| Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm | Q46963887 | ||
| The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes | Q47952461 | ||
| A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. | Q51051082 | ||
| How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. | Q53324180 | ||
| CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. | Q53351994 | ||
| Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL | Q56965918 | ||
| Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia | Q59194346 | ||
| A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas | Q74099333 | ||
| Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies | Q77299882 | ||
| Characterization of acute lymphoblastic leukemia progenitor cells | Q80310211 | ||
| Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial | Q80568663 | ||
| Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey | Q81187579 | ||
| PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia | Q82639838 | ||
| Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts | Q84569964 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 3814-3826 | |
| P577 | publication date | 2016-08-29 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies | |
| P478 | volume | 126 |
| Q48649390 | A compound chimeric antigen receptor strategy for targeting multiple myeloma |
| Q91744779 | A general view of CD33+ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy |
| Q33692070 | A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines |
| Q38754498 | Adoptive T-Cell Therapy for Solid Tumors |
| Q93039755 | Advances and Challenges of CAR T Cells in Clinical Trials |
| Q89128658 | Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies |
| Q33564364 | Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia |
| Q48334966 | An APRIL based chimeric antigen receptor for dual targeting of BCMA and TACI in Multiple Myeloma. |
| Q96762429 | An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia |
| Q57803767 | Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma |
| Q92668854 | Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains |
| Q45871879 | Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. |
| Q47103718 | Anti-CD19 resistance can "stem" from progenitors. |
| Q57024658 | Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas |
| Q39175440 | Antigen Loss Variants: Catching Hold of Escaping Foes |
| Q64070843 | Antigen Targets for the Development of Immunotherapies in Leukemia |
| Q92348410 | Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer |
| Q91240555 | Biologie, concepts et principes des CAR-T cells |
| Q48255324 | Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. |
| Q90677062 | CAR T Cell Therapy Progress and Challenges for Solid Tumors |
| Q55382852 | CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. |
| Q92245332 | CAR T cells for brain tumors: Lessons learned and road ahead |
| Q90287452 | CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies |
| Q97524803 | CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences |
| Q52658445 | CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? |
| Q39305346 | CAR T-cell therapy for lung cancer and malignant pleural mesothelioma |
| Q52689076 | CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. |
| Q90606767 | CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression |
| Q90705235 | CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV |
| Q56334080 | CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease |
| Q91240557 | CAR-T cells : indications actuelles en pédiatrie et perspectives de développement |
| Q39246685 | CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond |
| Q90231866 | CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies |
| Q58557050 | CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia |
| Q33655754 | CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis |
| Q58736815 | CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum |
| Q92190767 | CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma |
| Q89948326 | CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm |
| Q38737924 | Cancer Immunotherapy: Whence and Whither |
| Q92698902 | Cancer Stem Cells in Neuroblastoma: Expanding the Therapeutic Frontier |
| Q28072131 | Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies |
| Q64245424 | Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML) |
| Q47377609 | Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. |
| Q47193084 | Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy |
| Q91673629 | Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells |
| Q38600697 | Chimeric antigen receptor T-cell therapies for lymphoma |
| Q48337005 | Chimeric antigen receptor transduced T cells: Tuning up for the next generation |
| Q88573551 | Chimeric antigen receptor-modified T cells: CD19 and the road beyond |
| Q41558781 | Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia |
| Q33823270 | Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma |
| Q64005145 | Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia |
| Q48199074 | Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies |
| Q57455148 | Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success |
| Q39280002 | Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment |
| Q39200527 | Development of CAR T cells designed to improve antitumor efficacy and safety |
| Q47681393 | Discovery and application of immune biomarkers for hematological malignancies. |
| Q88098354 | Driving CARs on the uneven road of antigen heterogeneity in solid tumors |
| Q89032225 | Driving cars to the clinic for solid tumors |
| Q98771275 | Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment |
| Q47870235 | Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. |
| Q90334543 | Emerging Cellular Therapies for Cancer |
| Q48192887 | Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia |
| Q48195045 | Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia |
| Q99237937 | Engineering CAR T Cells to Target the HIV Reservoir |
| Q99237969 | Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies |
| Q60924201 | Engineering and Design of Chimeric Antigen Receptors |
| Q91847813 | Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors |
| Q91614877 | Engineering switchable and programmable universal CARs for CAR T therapy |
| Q57293724 | Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting |
| Q92337122 | Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors |
| Q92983054 | Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia |
| Q55380614 | Genetically enhanced T lymphocytes and the intensive care unit. |
| Q57106917 | Genetics and biology of prostate cancer |
| Q38615436 | Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy. |
| Q48556375 | Immune Checkpoint Blockade in Breast Cancer Therapy |
| Q64950921 | Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. |
| Q41573313 | Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment |
| Q92503954 | Immunotherapy in breast cancer |
| Q41183874 | Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies |
| Q59349994 | Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager |
| Q57059973 | Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell |
| Q64998779 | Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. |
| Q92980947 | Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape |
| Q47271647 | Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. |
| Q91670667 | Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies |
| Q90436838 | Mechanisms of failure of chimeric antigen receptor T-cell therapy |
| Q92150199 | Mechanisms of resistance to CAR T cell therapy |
| Q64102615 | Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies |
| Q90239914 | Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors |
| Q92482546 | Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model |
| Q41661175 | Natural Killer Cells: Angels and Devils for Immunotherapy |
| Q37658246 | New development in CAR-T cell therapy |
| Q94467230 | New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry |
| Q46824889 | Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression |
| Q89287784 | Pediatric Cancer Immunotherapy: Opportunities and Challenges |
| Q92666841 | Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers |
| Q90732577 | Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22 |
| Q64117924 | Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma |
| Q39130451 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy |
| Q33770150 | Prognostic factors and treatment of pediatric acute lymphoblastic leukemia |
| Q96231636 | Prognostic value of CD25/CD123 pattern of expression in acute myeloid leukemia patients with normal cytogenetic |
| Q90215603 | Programming CAR-T cells to kill cancer |
| Q50026306 | Progress in clinical studies of chimeric antigen receptor engineered T cells for treatment of childhood cancer |
| Q90453826 | Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor |
| Q38651711 | Reconstructing the immune system with lentiviral vectors |
| Q39059681 | Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors |
| Q47566513 | Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation |
| Q38761791 | Stem and progenitor cell alterations in myelodysplastic syndromes |
| Q64066845 | Switching on the green light for chimeric antigen receptor T-cell therapy |
| Q90608633 | Synthetic immunity by remote control |
| Q91522807 | T cell-engaging therapies - BiTEs and beyond |
| Q90475878 | TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells |
| Q64965331 | Target selection for CAR-T therapy. |
| Q58790069 | Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy |
| Q94545537 | Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells |
| Q43695979 | Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia |
| Q104495182 | Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy |
| Q64118716 | The Emergence of Universal Immune Receptor T Cell Therapy for Cancer |
| Q47820469 | The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia. |
| Q92354027 | The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells |
| Q98465729 | The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology |
| Q57177485 | The application of CAR-T cell therapy in hematological malignancies: advantages and challenges |
| Q89515386 | The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 |
| Q92633429 | The making and function of CAR cells |
| Q93062255 | The one-two punch (of CAR T cells) |
| Q39039017 | The promise of chimeric antigen receptor T cells (CARTs) in leukaemia |
| Q59360113 | The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma |
| Q40135347 | Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. |
| Q91871527 | Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies |
| Q59326961 | Universal CARs, universal T cells, and universal CAR T cells |
| Q88506528 | Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses |
| Q57156109 | WITHDRAWN: CAR T cells : indications actuelles en pédiatrie et perspectives de développement |
| Q90461296 | You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy |
| Q47141728 | mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting |
Search more.